Ribavirin: An effective treatment of Crimean-Congo Haemorrhagic Fever

Pakistan Journal of Medical Sciences

Volumn 20, Issue 3, 2004, Pages 201-206

  Sheikh, Azeem S ^a   Sheikh, Aqleem A ^b   Sheikh, Nadeem S ^c,e   Tariq, Muhammad ^d  

^a SHAIKH ZAYED HOSPITAL   (Pakistan)

^b Sandeman Provincial Teaching Hosp   (Pakistan)

^c BOLAN MEDICAL COLLEGE   (Pakistan)

^d UNIVERSITY OF BALOCHISTAN   (Pakistan)

^e Al Samad Medical Center   (Pakistan)

Author keywords

Anti viral drug; Balochistan; CCHF; Outbreak; Ribavirin

Indexed keywords

ANTIPYRETIC AGENT; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UTILIZATION; EPISTAXIS; FEMALE; FEVER; HEMATEMESIS; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOCYTOSIS; VIRUS HEMORRHAGIC FEVER;

EID: 4644342248     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hoogstral H. The epidemiology of tick-borne Crimean - Congo Haemorrhagic Fever in Asia, Europe and Africa. J Med Entomol 1979;15: 307-17.
2. Burney MI, Ghafoor A, Saleem M, Webb PA, Casals J. Nosocomal outbreak of Viral Haemorrhagic Fever caused by Crimean Haemorrhagic Fever-Congo virus in Pakistan, January 1976. Am J Trop Med Hyg 1980; 29: 941-7.
3. Suleman M, Muscat-Baron JM, Harries JR et al. Congo-Crimean Haemorrhagic Fever in Dubai. Lancet 1980; 2: 939-41.
4. Tantawi HH, Al-Moslih MI, Al-Janabi MI et al. Crimean-Congo Haemorrhagic Fever virus in Iraq: Isolation, identification & electron microscopy. Acta Virol 1980;24:464-7.
5. Saluzzo JF, Digoutte JP, Cornet M et al. Isolation of Crimean Congo Haemorrhagic Fever and Rift Valley Fever Viruses in Upper Volta. Lancet 1984; 1: 1179.
6. Saluzzo JF, Aubry P, McCormick J et al. Haemorrhagic Fever caused by Crimean-Congo Haemorrhagic Fever Virus in Mauritania. Trans R Soc Trop Med Hyg 1985;79:268.
7. Yen YC, Kong LX, Lee L et al. Characteristics of Crimen-Congo Haemorrhagic Fever Virus (Xinjiang Strain) in China. Am J Trop Med Hyg 1985; 34 (6): 1179-82.
8. Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP et al. Epidemiologic and clinical features of Crimean-congo Haemorrhagic Fever in Southern Africa. Am J Trop Med Hyg 1987; 36: 120-32.
9. Leshchinskaya EV. Clinical picture of Crimean Haemorrhagic Fever in Russia. Trudy Inst Polio virus Entsef Akad Med Nauk SSSR 1965; 7: 226-36.
10. Casals J. Antigenic similarity between the virus causing Crimean Haemorrhagic Fever and Congo-Virus. Proc Soc Exp Biol Med 1969; 131: 233-6.
11. Fisher-Hoch SP, Simpson DIH. Dangerous pathogens. Br Med Bull 1985; 41: 391-5.
12. rd ed. Philadelphia: Raven Press 1996.
13. Joubert JR, King JB, Rossoouw DJ, Cooper R. A nosocomial outbreak of Crimean-Congo Haemorrhagic Fever at Tygerberg Hospital: Part III clinical pathology and pathogenesis. S Afr Med J 1985; 68: 722-8.
14. CDC Update. Management of patients with suspected Viral Haemorrhagic Fever - United States, MMWR 1995; 44: 475-9.
15. CDC. Management of patients with suspected Viral Haemorrhagic Fever. MMWR 1988; 37: 1-16.
16. Baron RC, McCormick JB, Zubair OA. Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. Bull WHO 1983; 61: 997-1003.
17. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo Haemorrhagic Fever viral infectivity yields in-vitro by Ribavirin. Am J Trop Med Hyg 1989;41:591-5.
18. McCormick JB, King IJ, Webb PA et al. Lassa fever: effective therapy with Ribavirin. N Eng J Med 1986; 314: 20-6.
19. Laskin OL, Longstreth JA, Hart CC et al. Ribavirin disposition in high-risk patients for acquired immunedeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546-55.
20. Wilson SZ, Gilbert BE, Quarles JM et al. Treatment of influenza A (HINI) virus infection with Ribavirin aerosol. Antimicrob Agents Chemother 1984; 26: 200-3.
21. Huggins JW, Hsiang CM, Cosgriff TM et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous Ribavirin therapy of Haemorrhagic Fever with renal syndrome. J Infect Dis 1991; 164: 1419-27.
22. Canonico PG, Kastello MD, Spears CT, Brown JR et al. Effects of Ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74: 155-62.
23. th Ed. Pergamon Press Inc. New York 1991; 1182-1201.
24. Hayden FG et al. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980; 18: 536-41.
25. 2, aimantadine hydrochloride and Ribavirin inhibition of influenza virus replication in-vitro. Antimicrob Agents Chemother 1984; 25: 53-7.
26. Vogt MW et al. Ribavirin antagonizes the effects of azidothymidine on HIV replication. Science 1987; 235: 1376-9.
27. Fisher - Hoch SP et al. Crimean - Congo Haemorrhagic Fever treated with oral Ribavirin. Lancet 1995; 346:472-5.
28. Holmes GP et al. Lassa fever in the United States: investigation of a case and new guidelines for management. N Engl J Med 1990; 323: 1120-3.
29. Van de Wal BW, Joubert JR et al. A nosocomial outbreak of Crimean-Congo Haemorrhagic Fever at Tygerberg Hospital, Part-IV. Preventive and prophylactic measures. S Afr Med J 1985; 68: 729-36.
30. Roberts RB, Laskin O et al. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 42: 365-73.
31. Clinical Investigator's Brochure, ICH Pharmaceuticals Inc, Irvine CA. Hillyard IW. The preclinical toxicological safety of Ribavirin. In: Smith RA, Kirkpatrick W (eds). Ribavirin, a broad-spectrum antiviral agent. Academic Press, New York 1980; 58-71.